Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)



Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session and finished the day at $3.84. Traded volume was 9.38million shares in the last session and the average volume of the stock remained 2.56million shares. The beta of the stock remained 2.08. Zogenix, Inc. (NASDAQ:ZGNX) insider ownership is 0.10%.

Boston Scientific Corp. (NYSE:BSX)’s SVP David A. Pierce sold 5,316 shares of Boston Scientific Corp. stock in a transaction that occurred on Thursday, March 6th. Boston Scientific Corporation (NYSE:BSX) rose 1.27 percent to $13.55 yesterday on volume of BSX 9.38million shares. The intra-day range of the stock was $13.43 to $13.59. Boston Scientific Corporation (NYSE:BSX) has a market capitalization of $17.94billion.

Beleaguered biotech firm Galena Biopharma Inc (NASDAQ:GALE) is facing another lawsuit over insider stock sales filed by purchasers of the company’s stock. Galena Biopharma Inc (NASDAQ:GALE)’s stock on Mar 06, 2014 reported a decrease of -10.82% to the closing price of $3.46. Its fifty two weeks range is $1.65 -$7.77. The total market capitalization recorded $364.12billion. The overall volume in the last trading session was 10.17million shares. In its share capital, Galena Biopharma Inc (NASDAQ:GALE) has 87.32million outstanding shares.

A new, highly effective drug for treating hepatitis C—hailed as a cure for the disease—costs up to $84,000 per person, and is raising questions about the affordability of life-saving medications. In the past, the only way to cure hepatitis C has been with a liver transplant, so the new drugs, including Gilead Science Inc. (NASDAQ:GILD)’s Sovaldi, are good news for patients. On Wednesday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) dropped -3.56% to close the day at $79.92. Company return on investment (ROI) is 28.60% and its monthly performance is recorded as -2.56%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is 10.36%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone